Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AdVhAFP is a recombinant, replication-deficient adenoviral vector engineered to express the human alpha-fetoprotein (AFP) gene. It is designed as an immunotherapy for hepatocellular carcinoma (HCC), a malignancy that frequently overexpresses AFP as a tumor-associated antigen. The vector is primarily used to transduce dendritic cells (DCs) ex vivo or administered directly to induce and expand AFP-specific CD4+ helper and CD8+ cytotoxic T-cell responses. By utilizing an adenoviral delivery system, the therapy aims to overcome immunological tolerance to AFP, which is a self-antigen, thereby promoting a robust Th1-skewed immune response capable of recognizing and eliminating AFP-positive tumor cells.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on AdVhAFP.